Swiss Biotech DaySwiss Biotech Report reporting record turnoverThe Swiss biotech sector proved robust growth in 2023. Revenues in 2023 increased by CHF500m to CHF7.3bn. Capital investment grew to CHF2bn – just betweeen 2021 (CHF3.4bn) and 2022 (CHF1.3bn). more ➔
Drug DiscoveryIpsen puts US$1.8bn in pipeline expansion in movement disordersIpsen SA and RNA splicing modifier specialist Skyhawk Therapeutics Inc have entered a US$1.8bn licencing option deal in rare neurological disorders. more ➔
AMDSeabelife SAS to develop next-gen dry AMD drugFrench drug maker Seabelife SAS will use a €1.5m price money to develop a new dual-acting necroptosis blocker to reduce cell death in geographic atrophy. more ➔
AmphiStar BVfinancingAmphiStar BV secures €6m to expand productionWaste based biosurfactants producer Amphistar BV has closed a €6m funding round led by the European Circular Bioeconomy Fund (ECBF), Qbic III and Flanders Future Tech Fund (FFTF). more ➔
HIVNaobios and Sumagen partner to develop HIV vaccineVaccine maker Sumagen Co. Ltd has launched a cGMP manufacturing partnership with French Naobios SAS for clinical testing of Sumagen’s inactivated HIV vaccine candidate. more ➔
Industrial BiotechSolar Foods starts Factory01Finnish Solar Foods Oy has started microbial production of its protein powder Solein in Factory 01, Solar Foods’ first commercial-scale production facility in Vantaa, Finland. more ➔
ApprovalShock: Adrenomed AG gets FDA fast track designationGerman AdrenoMed AG has got FDA Fast Track designation for its targeted septic shock medicine enibarcimab that restores endothel integrity. more ➔
CollaborationLonza AG enters R&D collaboration with NeuroSense Therapeutics LtdALS specialist NeuroSense Therapeutics Ltd announces it will be collaborating with Swiss Lonza AG to identify exosome-based biomarkers to advance theranostics in neurodegeneration. more ➔
NeurologyLonza AG enters R&D collaboration with NeuroSense Therapeutics LtdALS specialist NeuroSense Therapeutics Ltd announces it will be collaborating with Swiss Lonza AG to identify exosome-based biomarkers to advance theranostics in neurodegeneration. more ➔
AcquisitionEssential Pharma acquires Renaissance Pharma LtdEssential Pharma has acquired Renaissance Pharma Ltd to commercialise the company’s Phase II program Hu14.18K322A in pedriatric high-risk neuroblastoma. more ➔
AmphiStar BV
